| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $6,008,569 | 2 | 40 |
Sells | $725,952 | 3 | 60 |
| Bancel Stephane | Chief Executive Officer | 1 | $5M | 0 | $0 | $5M |
| SAGAN PAUL | director | 1 | $1M | 0 | $0 | $1M |
| Hussain Abbas | director | 0 | $0 | 2 | $22,646 | $-22,646 |
| AFEYAN NOUBAR | director | 0 | $0 | 1 | $703,306 | $-703,306 |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Moderna, Inc. have bought $6.01M and sold $725,952 worth of Moderna, Inc. stock.
On average, over the past 5 years, insiders at Moderna, Inc. have bought $6.01M and sold $643.35M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Bancel Stephane (Chief Executive Officer) — $5M. SAGAN PAUL (director) — $1M.
The last purchase of 31,620 shares for transaction amount of $1M was made by SAGAN PAUL (director) on 2025‑03‑03.
| 2025-12-11 | Sale | AFEYAN NOUBAR | director | 23,853 0.0061% | $29.48 | $703,306 | +14.14% | |
| 2025-12-09 | Sale | Hussain Abbas | director | 504 0.0001% | $27.60 | $13,910 | +17.83% | |
| 2025-06-11 | Sale | Hussain Abbas | director | 312 <0.0001% | $28.00 | $8,736 | -2.20% | |
| 2025-03-03 | Bancel Stephane | Chief Executive Officer | 160,314 0.0429% | $31.22 | $5M | -10.27% | ||
| 2025-03-03 | SAGAN PAUL | director | 31,620 0.0086% | $31.76 | $1M | -10.27% | ||
| 2024-12-09 | Sale | Klinger Shannon Thyme | Chief Legal Officer | 529 0.0001% | $44.68 | $23,637 | -39.74% | |
| 2024-12-03 | Sale | Hoge Stephen | President | 314 <0.0001% | $43.30 | $13,595 | -35.33% | |
| 2024-12-03 | Sale | Klinger Shannon Thyme | Chief Legal Officer | 112 <0.0001% | $43.30 | $4,849 | -35.33% | |
| 2024-11-29 | Sale | Hoge Stephen | President | 291 <0.0001% | $42.79 | $12,452 | -35.93% | |
| 2024-11-29 | Sale | Klinger Shannon Thyme | Chief Legal Officer | 1,418 0.0004% | $42.79 | $60,675 | -35.93% | |
| 2024-11-29 | Sale | Mock James M | Chief Financial Officer | 1,420 0.0004% | $42.79 | $60,761 | -35.93% | |
| 2024-11-11 | Sale | Hoge Stephen | President | 277 <0.0001% | $46.10 | $12,771 | -34.70% | |
| 2024-10-07 | Sale | Mock James M | Chief Financial Officer | 715 0.0003% | $60.12 | $42,986 | -46.30% | |
| 2024-09-09 | Sale | Klinger Shannon Thyme | Chief Legal Officer | 551 0.0002% | $73.57 | $40,539 | -56.11% | |
| 2024-09-03 | Sale | Hoge Stephen | President | 318 0.0001% | $76.99 | $24,483 | -53.68% | |
| 2024-09-03 | Sale | Klinger Shannon Thyme | Chief Legal Officer | 114 <0.0001% | $76.99 | $8,777 | -53.68% | |
| 2024-08-29 | Sale | Hoge Stephen | President | 300 0.0001% | $78.03 | $23,408 | -56.34% | |
| 2024-08-29 | Sale | Klinger Shannon Thyme | Chief Legal Officer | 162 <0.0001% | $78.03 | $12,640 | -56.34% | |
| 2024-08-29 | Sale | Mock James M | Chief Financial Officer | 162 <0.0001% | $78.03 | $12,640 | -56.34% | |
| 2024-08-28 | Sale | Klinger Shannon Thyme | Chief Legal Officer | 1,319 0.0006% | $79.39 | $104,722 | -56.73% |
| Bancel Stephane | Chief Executive Officer | 9210686 2.3573% | $449.44M | 1 | 416 | |
| SAGAN PAUL | director | 312027 0.0799% | $15.23M | 2 | 1 | +262.16% |
| AFEYAN NOUBAR | director | 3924 0.001% | $191,471.58 | 0 | 90 | |
| Hussain Abbas | director | 1515 0.0004% | $73,924.43 | 0 | 2 | |
| Trieu Vuong | Chairman of the Board | 11117141 2.8452% | $542.46M | 2 | 0 | |
| Flagship Ventures Fund IV General Partner LLC | 6420766 1.6433% | $313.3M | 0 | 5 | ||
| Novartis Bioventures Ltd | 10 percent owner | 2495065 0.6386% | $121.75M | 0 | 6 | |
| Pryor Cashman LLP | 10 percent owner | 1591959 0.4074% | $77.68M | 0 | 5 | |
| Hoge Stephen | President | 1443904 0.3695% | $70.46M | 0 | 185 | |
| Kim Lorence H. | Chief Financial Officer | 1202510 0.3078% | $58.68M | 0 | 15 | |
| Ramelli Joseph W. | Chief Executive Officer | 440653 0.1128% | $21.5M | 4 | 0 | |
| Duffy Timothy M | Chief Business Officer | 56395 0.0144% | $2.75M | 0 | 1 | |
| Costantino Henry R | CSO - Delivery | 24485 0.0063% | $1.19M | 0 | 3 | |
| KANIA EDWIN M JR | 10 percent owner | 23847 0.0061% | $1.16M | 0 | 3 | |
| Nader Francois | 20607 0.0053% | $1.01M | 0 | 1 | ||
| Klinger Shannon Thyme | Chief Legal Officer | 20446 0.0052% | $997,662.57 | 0 | 25 | |
| Andres Juan | See remarks | 12803 0.0033% | $624,722.39 | 0 | 171 | |
| Mock James M | Chief Financial Officer | 11066 0.0028% | $539,965.47 | 0 | 12 | |
| FRENCH J MICHAEL | CEO | 10000 0.0026% | $487,950.00 | 1 | 0 | |
| LEE JENNIFER LING | Chief Accounting Officer | 4419 0.0011% | $215,625.11 | 0 | 1 | |
| HUTT PETER BARTON | director | 3924 0.001% | $191,471.58 | 0 | 2 | |
| Garay Arpa | Chief Commercial Officer | 3690 0.0009% | $180,053.55 | 0 | 3 | |
| Meline David W | Chief Financial Officer | 2857 0.0007% | $139,407.32 | 0 | 3 | |
| HENDERSON LORI M. | General Counsel and Secretary | 901 0.0002% | $43,964.30 | 0 | 29 | |
| Burton Paul | Chief Medical Officer | 954 0.0002% | $46,550.43 | 0 | 2 | |
| NABEL ELIZABETH G | director | 0 0% | $0 | 0 | 2 | |
| Zaks Tal Zvi | Chief Medical Officer | 0 0% | $0 | 0 | 72 |
$961,890,236 | 276 | 22.46% | $20.02B | |
$211,610,344 | 91 | 38.45% | $10.91B | |
$2,765,836 | 72 | 20.00% | $10.8B | |
$2,449,191,716 | 58 | 16.50% | $77.83B | |
$11,789,714 | 49 | 14.35% | $33.32B | |
$323,530,732 | 48 | 29.90% | $47.29B | |
$88,307,390 | 38 | -1.70% | $10.25B | |
$19,233,721 | 36 | 70.14% | $11.87B | |
$13,655,378 | 35 | 17.13% | $21.21B | |
$15,836,193 | 25 | 17.98% | $120.1B | |
$415,090,639 | 19 | -14.04% | $15.01B | |
$143,065,458 | 17 | 8.01% | $22.75B | |
$152,272,932 | 16 | -10.78% | $17.54B | |
$627,701,115 | 15 | 145.68% | $12.28B | |
$284,820 | 10 | 45.67% | $13B | |
$948,235 | 8 | 15.56% | $10.62B | |
$40,276,273 | 4 | 34.57% | $15.7B | |
$36,900,000 | 3 | -9.12% | $10.94B | |
Moderna, Inc. (MRNA) | $999,989 | 1 | 262.16% | $19.07B |
| Increased Positions | 270 | +33.37% | 19M | +6.67% |
| Decreased Positions | 334 | -41.29% | 33M | -11.39% |
| New Positions | 69 | New | 3M | New |
| Sold Out Positions | 99 | Sold Out | 5M | Sold Out |
| Total Postitions | 745 | -7.91% | 277M | -4.72% |
| Vanguard Group Inc | $1.27M | 10.53% | 41.19M | -523,410 | -1.25% | 2025-09-30 |
| Blackrock, Inc. | $911,232.00 | 7.55% | 29.53M | +916,447 | +3.2% | 2025-09-30 |
| Baillie Gifford & Co | $674,188.00 | 5.59% | 21.85M | -247,458 | -1.12% | 2025-09-30 |
| State Street Corp | $527,971.00 | 4.38% | 17.11M | -162,036 | -0.94% | 2025-09-30 |
| Fmr Llc | $379,711.00 | 3.15% | 12.3M | -7M | -37.37% | 2025-09-30 |
| Morgan Stanley | $307,434.00 | 2.55% | 9.96M | +2M | +22.94% | 2025-09-30 |
| Geode Capital Management, Llc | $285,435.00 | 2.37% | 9.25M | +372,072 | +4.19% | 2025-09-30 |
| Invesco Ltd. | $253,551.00 | 2.1% | 8.22M | +1M | +15.7% | 2025-09-30 |
| Theleme Partners Llp | $249,003.00 | 2.06% | 8.07M | +200,000 | +2.54% | 2025-09-30 |
| Two Sigma Investments, Lp | $232,375.00 | 1.93% | 7.53M | +570,773 | +8.2% | 2025-09-30 |